BR112016005361B8 - Composto, composição, e, uso de um composto - Google Patents

Composto, composição, e, uso de um composto

Info

Publication number
BR112016005361B8
BR112016005361B8 BR112016005361A BR112016005361A BR112016005361B8 BR 112016005361 B8 BR112016005361 B8 BR 112016005361B8 BR 112016005361 A BR112016005361 A BR 112016005361A BR 112016005361 A BR112016005361 A BR 112016005361A BR 112016005361 B8 BR112016005361 B8 BR 112016005361B8
Authority
BR
Brazil
Prior art keywords
compound
composition
compounds
inhibitors
tricyclic
Prior art date
Application number
BR112016005361A
Other languages
English (en)
Other versions
BR112016005361B1 (pt
BR112016005361A8 (pt
Inventor
Finn John
William Tari Leslie
Chen Zhiyong
Zhang Junhu
Phillipison Douglas
Joong Lee Suk
Trzoss Michael
Bensen Daniel
Li Xiaoming
Teng Min
Ong Voon
John Borchardt Allen
To Lam Thanh
C Lightstone Felice
E Wong Sergio
B Nguyen Toan
Original Assignee
L Livermore Nat Security Llc
Merck Sharp & Dohme
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L Livermore Nat Security Llc, Merck Sharp & Dohme, Merck Sharp & Dohme Llc filed Critical L Livermore Nat Security Llc
Publication of BR112016005361A8 publication Critical patent/BR112016005361A8/pt
Publication of BR112016005361B1 publication Critical patent/BR112016005361B1/pt
Publication of BR112016005361B8 publication Critical patent/BR112016005361B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

INIBIDORES DE GIRASE TRICÍCLICA, COMPOSIÇÃO, FORMA DE DOSAGEM, EMBALAGEM E DISPOSITIVO DISPENSADOR QUE OS COMPREENDE, BEM COMO USO DOS MESMOS. São aqui divulgados compostos tendo a estrutura de Fórmula I e sais, ésteres e pró-fármacos farmaceuticamente adequados dos mesmos que são úteis como inibidores da girase tricíclica antibacterianamente eficazes. Composições farmacêuticas, usos e métodos relacionados de preparação dos compostos são também contemplados.
BR112016005361A 2013-09-11 2014-09-10 Composto, composição, e, uso de um composto BR112016005361B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361876688P 2013-09-11 2013-09-11
US61/876,688 2013-09-11
PCT/US2014/055019 WO2015038661A1 (en) 2013-09-11 2014-09-10 Tricyclic gyrase inhibitors

Publications (3)

Publication Number Publication Date
BR112016005361A8 BR112016005361A8 (pt) 2018-01-30
BR112016005361B1 BR112016005361B1 (pt) 2022-12-27
BR112016005361B8 true BR112016005361B8 (pt) 2023-04-18

Family

ID=52666234

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016005361A BR112016005361B8 (pt) 2013-09-11 2014-09-10 Composto, composição, e, uso de um composto

Country Status (8)

Country Link
US (1) US10385055B2 (pt)
EP (1) EP3044225A4 (pt)
CN (1) CN105899511B (pt)
AU (1) AU2014318838B2 (pt)
BR (1) BR112016005361B8 (pt)
RU (1) RU2680138C2 (pt)
WO (1) WO2015038661A1 (pt)
ZA (1) ZA201601628B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR085806A1 (es) * 2011-03-15 2013-10-30 Trius Therapeutics Inc Inhibidores triciclicos de girasa
WO2014043272A1 (en) * 2012-09-12 2014-03-20 Trius Therapeutics Inc. Tricyclic gyrase inhibitors for use as antibacterial agents
US20210070747A1 (en) 2017-03-24 2021-03-11 Taisho Pharmaceutical Co., Ltd. 2(1h)-quinolinone derivative
WO2018178041A1 (en) 2017-03-30 2018-10-04 F. Hoffmann-La Roche Ag Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection
CN110801455B (zh) * 2019-11-12 2020-06-02 河北医科大学第二医院 用于治疗mrsa的药物组合物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2158127C2 (ru) * 1994-12-23 2000-10-27 Варнер-Ламберт Компани Способы ингибирования тирозинкиназы рецептора эпидермального фактора роста, азотсодержащие трициклические соединения, фармацевтическая композиция, предназначенная для введения ингибитора тирозинкиназы рецептора эпидермального фактора роста, например, erb-b2, erb-b3 или erb-b4, и противозачаточная композиция
US6874491B2 (en) 2003-01-15 2005-04-05 William Bednar Crossbow rope cocking device
DE602004022318D1 (de) * 2003-10-14 2009-09-10 Supergen Inc Proteinkinaseinhibitoren
US7982035B2 (en) * 2007-08-27 2011-07-19 Duquesne University Of The Holy Spirit Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof
AR085806A1 (es) * 2011-03-15 2013-10-30 Trius Therapeutics Inc Inhibidores triciclicos de girasa
WO2014043272A1 (en) * 2012-09-12 2014-03-20 Trius Therapeutics Inc. Tricyclic gyrase inhibitors for use as antibacterial agents

Also Published As

Publication number Publication date
CN105899511A (zh) 2016-08-24
BR112016005361B1 (pt) 2022-12-27
AU2014318838A1 (en) 2016-03-24
RU2016113494A3 (pt) 2018-05-31
WO2015038661A1 (en) 2015-03-19
RU2680138C2 (ru) 2019-02-18
EP3044225A4 (en) 2017-03-08
CN105899511B (zh) 2019-06-07
US20160222015A1 (en) 2016-08-04
US10385055B2 (en) 2019-08-20
AU2014318838B2 (en) 2018-06-07
EP3044225A1 (en) 2016-07-20
RU2016113494A (ru) 2017-10-16
ZA201601628B (en) 2017-06-28
BR112016005361A8 (pt) 2018-01-30

Similar Documents

Publication Publication Date Title
CY1121418T1 (el) Παρεμποδιστες ιου ηπατιτιδας c
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
BR112014007134A2 (pt) usos de um composto da fórmula (b), compostos, composição farmacêutica, método de preparação do composto e uso de uma quantidade efetiva de um composto
NI201400108A (es) Compuestos de heterociclilo
BR112013023266A8 (pt) Inibidores da girase tricíclicos
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
CO2018002211A2 (es) Piridinona dicarboxamida para su uso como inhibidores de bromodominio
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
EA201301240A1 (ru) Полиморфная форма бензоата линаглиптина
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
GT201500094A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
EA201492287A1 (ru) Дейтерированные производные руксолитиниба
DOP2015000170A (es) Compuestos químicos
GT201400059A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos
GT201500235A (es) Estra -1,3,5 (10) , 16- tetraeno -3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1c3)
BR112016005361B8 (pt) Composto, composição, e, uso de um composto
BR112016005317A2 (pt) derivados de quinazolina e seu uso como inibidores de dna metiltransferase
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
EA201591259A1 (ru) Твёрдые формы производного хиназолина и их применение в качестве ингибитора braf

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/09/2014, OBSERVADAS AS CONDICOES LEGAIS

B25A Requested transfer of rights approved

Owner name: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) ; MERCK SHARP AND DOHME LLC (US)